Smarter leaders trust GlobalData

Data Insights Innovation in pharma: SMAC mimetic peptides

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

F. Hoffmann-La Roche Ltd

Philip Morris International Inc

Royal Caribbean Cruises Ltd

3-D Matrix Ltd

Agios Pharmaceuticals Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

SMAC mimetic peptides is a key innovation area in the pharmaceutical industry

SMAC (Second Mitochondria-Derived Activator of Caspases) mimetic peptides are synthetic compounds designed to mimic the actions of the endogenous protein SMAC/DIABLO (Direct IAP-Binding Protein with Low pI). These peptides have gained significant attention in cancer research and the development of potential cancer therapies due to their role in regulating cell death and apoptosis. They can bind to IAPs, specifically targeting proteins such as XIAP (X-linked inhibitor of apoptosis protein), cIAP1 (cellular inhibitor of apoptosis protein 1), and cIAP2 (cellular inhibitor of apoptosis protein 2).

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 1260 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of SMAC mimetic peptides.

Key players in SMAC mimetic peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to SMAC mimetic peptides

Immatics is one of the leading patent filers in SMAC mimetic peptides. Also known as Immatics Biotechnologies, Immatics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company specializes in the field of T-cell receptor (TCR) therapies and cancer immunotherapy. Immatics is known for its efforts to harness the power of the immune system to target and combat cancer cells. F. Hoffmann-La Roche and Bristol-Myers Squibb are some of the other key patent filers in SMAC mimetic peptides.

In terms of application diversity, 3-D Matrix leads the pack, while Agios Pharmaceuticals and Autoimmune Technologies stood in second and third positions, respectively.

By means of geographic reach, Pierre Fabre Foundation held the top position, followed by Autoimmune Technologies and Baxter International.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.